Alex Brill, CEO of Matrix Global Advisors, gave a presentation during the GRx+Biosims 2018 conference in Baltimore, Maryland that discussed the barriers to increased uptake of biosimilars in the United States, and how to address those issues.
Alex Brill, CEO of Matrix Global Advisors, gave a presentation during the GRx+Biosims 2018 conference in Baltimore, Maryland that discussed the barriers to increased uptake of biosimilars in the United States, and how to address those issues.
As Brill sees it, there are 4 main categories of barriers to biosimilar uptake: reference product manufacturers, biosimilar manufacturers, policy, and education.
In terms of reference product manufactures, Brill noted that drug developers have put up hurdles to biosimilar uptake in the form of their rebate practices. “Certain reference product manufacturers have conducted aggressive strategies with payers where if a payer were to put a biosimilar on its formulary, it would lose the rebate discount provided by the reference product,” said Brill.
Read more about exclusionary contracting.
The solution, he says, comes down to which stakeholder group is being addressed. For payers, he recommends adopting a longer-term perspective when negotiating contracts and designing formularies. For employers, he said the key is to identify cost-saving opportunities for their businesses as well as for their patients. Finally, for drug makers, he said that manufacturers need to ensure fair market access for biosimilars.
Certain barriers to uptake are also “natural” as Brill puts it, such as market uncertainty for consumers and biosimilar manufacturers alike. “These products are expensive and take time to develop. There’s also a lot of uncertainty with regard to other competitors…how many other people are pursuing access to the same market for the same reference product?”
In addition, biosimilars have seen relatively limited market share thus far, which could potentially be due to discounts not being sufficient. To address these challenges, payers should institute policies to drive greater biosimilar utilization, and likewise, manufacturers need to be able to offer competitive contracting terms.
As far as policy is concerned, Brill believes the United States is moving in the right direction. The recent changes on the payment front from CMS were positive steps, but there remains more to do. “There’s an opportunity right now for relevant agencies to reevaluate the market and make sure that there are not unnecessary barriers that they’re imposing on this market,” he said.
Challenges such as the “patent thickets” that have been created, wherein a reference product developer looks to protect itself from competition by registering more patents, is something that law makers will need to address and hopefully do away with, according to Brill.
Finally, one of the biggest challenges to biosimilar uptake is the lack of stakeholder education and awareness. There is currently very limited prescribing experience, and healthcare providers have largely remained hesitant when it comes to prescribing these products to patients. Education should be provided not only to the patient and to the physician, but to the payers as well so that every stakeholder understands the what the product is, how it works, and how it should be paid for.
“No one challenge is any worse than another, but it needs a holistic approach of working across these barriers. Patient groups, industry, physician groups, and the FDA itself can play an important role in educating and informing the market,” said Brill.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.